Skip to content

Application of 18F-FAPI PET/CT in the Diagnosis of Malignant Tumors: A Prospective, Diagnostic Clinical Study

Application of 18F-FAPI PET/CT in the Diagnosis of Malignant Tumors: A Prospective, Diagnostic Clinical Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500113788
Enrollment
Unknown
Registered
2025-12-03
Start date
2023-11-08
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with suspected malignant tumors

Interventions

Gold Standard:The pathological result is the gold standard
Index test:18F-FAPI PET/CT imaging

Sponsors

Peking University Shenzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The subject voluntarily participates in this study and has signed the informed consent form; 2. Age >= 18 years and <= 80 years (based on the date of signing the informed consent form), regardless of gender; 3. Patients suspected of having malignant tumors but without confirmed pathological results; 4. Subjects obtain pathological results within two weeks after undergoing 18F-FAPI PET/CT imaging; 5. Performance status score of 0–1; 6. Expected survival time longer than 12 months; 7. Female subjects of childbearing potential, male subjects, and female partners of male subjects agree to use reliable contraception (e.g., abstinence, sterilization, oral contraceptives, depot medroxyprogesterone acetate, or subdermal contraceptive implants) for 6 months after the last infusion of study drug; 8. Willing and able to comply with scheduled visits, diagnostic procedures, clinical laboratory tests, and other study procedures.

Exclusion criteria

Exclusion criteria: 1.Have a history of any other malignant tumors within the past 5 years; 2.Previously used radioactive nuclides and the time interval from the administration of this study is less than 10 physical half - lives; 3.Currently participating or planning to participate in any drug or device clinical trials during the research period; 4.Unable to lie flat or remain still during a PET scan, or intolerant of PET scans; 5.Those with a history of fracture or anemia in the past 1 year; 6.Subjects with abnormalities in physical examinations, ECG, and clinical laboratory tests during the screening period, who, as determined by the investigator, may affect safety or compliance;

Design outcomes

Primary

MeasureTime frame
Sensitivity;Specificity;Accuracy rate;

Countries

China

Contacts

Public ContactDong Mengjie

Peking University Shenzhen Hospital

Dongmengjie@126.com+86 18257173283

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026